VBVirginie Beray-Berthat

Virginie Beray-Berthat

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Virginie Beray-Berthat has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Benoît Barsacq

    EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France

    1 shared publication
  • Bruno Palmier

    EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France

    1 shared publication
  • Bérard Coqueran

    EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France

    1 shared publication
  • Catherine Marchand-Leroux

    Université Paris Descartes

    1 shared publication
  • Charlotte Abbou

    EA4475 - “Pharmacologie de la Circulation Cérébrale”, Faculté de Pharmacie de Paris, Université Paris Descartes, Université Sorbonne Paris Cité, Paris, France

    1 shared publication
  • Dominique Lerouet

    Université de Paris, Inserm UMR-S 1144—Optimisation Thérapeutique en Neuropsychopharmacologie, Faculté de Pharmacie de Paris, 4 Avenue de l’Observatoire, 75006 Paris, France

    1 shared publication

Latest Publications

  • Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice

    by Mohamad El Amki, Dominique Lerouet, Marie Garraud, Fei Teng, Virginie Beray-Berthat, Bérard Coqueran, Benoît Barsacq, Charlotte Abbou, Bruno Palmier, Catherine Marchand-Leroux, et al.

    Benefits from thrombolysis with recombinant tissue plasminogen activator (rt-PA) after ischemic stroke remain limited due to a narrow therapeutic window, low reperfusion rates, and increased risk of hemorrhagic transformations (HT). Experimental data showed that rt-PA enhances the post-ischemic activation of poly(ADP-ribose)polymerase (PARP) which in turn contributes to blood-brain barrier injury. The aim of the present study was to evaluate whether PJ34, a potent PARP inhibitor, improves poor reperfusion induced by delayed rt-PA administration, exerts vasculoprotective effects, and finally increases the therapeutic window of rt-PA. Stroke was induced by thrombin injection (0.75 UI in 1 μl) in the left middle cerebral artery (MCA) of male Swiss mice. Administration of rt-PA (0.9 mg kg−1) or saline was delayed for 4 h after ischemia onset. Saline or PJ34 (3 mg kg−1) was given intraperitoneally twice, just after thrombin injection and 3 h later, or once, 3 h after ischemia onset. Reperfusion was evaluated by laser Doppler, vascular inflammation by immunohistochemistry of vascular cell adhesion molecule-1 (VCAM-1) expression, and vasospasm by morphometric measurement of the MCA. Edema, cortical lesion, and sensorimotor deficit were evaluated. Treatment with PJ34 improved rt-PA-induced reperfusion and promoted vascular protection including reduction in vascular inflammation (decrease in VCAM-1 expression), HT, and MCA vasospasm. Additionally, the combined treatment significantly reduced brain edema, cortical lesion, and sensorimotor deficit. In conclusion, the combination of the PARP inhibitor PJ34 with rt-PA after cerebral ischemia may be of particular interest in order to improve thrombolysis with an extended therapeutic window.